News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy
Photo: The Lancet Haematology/Twitter
May 18, 2023, 14:56

Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy

NEW: Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy showed promising activity in terms of PFS in older patients with B-cell ALL: results of a phase 2 trial

Source: The Lancet Haematology/Twitter

blinatumomab Inotuzumab ozogamicin phase 2 trial The Lancet Haematolog
Special Coverage
Societies
Dec 23, 2024, 13:03
Considerations for Central Venous Catheter Selection and Maintenance Care - SIOP
Insight
Dec 23, 2024, 12:59
Nevena Randjelovic is the winner of the European School of Oncology College Voices Contest - SPCC
Science
Dec 23, 2024, 12:55
Nelson Dusetti: Our European project on pancreatic cancer
Blog
Dec 23, 2024, 12:51
Clinical characteristics of EGFR-ctDNA shedders in EGFR-NSCLC patients - RolfoLab
Science
Dec 23, 2024, 12:47
Giuseppe Banna: Selpercatinib for RET fusion+ NSCLC by Benjamin Besse et al.
Blog
Dec 23, 2024, 12:47
Arsela Prelaj: The program of the 3rd edition of the AI for Oncology conference
Science
Dec 23, 2024, 12:33
Elizabeth McKenna: Multimodal Spatial Profiling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma
Science
Dec 23, 2024, 12:23
Paolo Tarantino: PostMONARCH is out in Journal of Clinical Oncology
Science
Dec 23, 2024, 12:19
Anirban Maitra: Preclinical data on potential combination to overcome KRASi resistance
Blog
Dec 23, 2024, 12:11
Five articles suggested by Yüksel Ürün
Blog
Dec 23, 2024, 12:00
Bertrand Delsuc: Refreshed Breast Cancer Map
Drugs
Dec 23, 2024, 11:55
Talha Badar: Venetoclax and Azacitidine for elderly AML ineligible for intensive Induction